Keywords
Proton pump inhibitors, esomeprazole, cytoprotector, rebamipid, preepithelial
Abstract
One of the urgent tasks in modern medicine is the development of innovative treatment regimens with high clinical efficacy. In recent years, a distinctive feature of modern pharmaceutical economics is the choice of methods of analysis, which allows to conduct a cross-assessment of the effectiveness of drugs, costs and identify the most clinically and economically feasible schemes of therapy. The use of proton pump inhibitors (PPI) and prokinetic drugs as a means of primary therapy of acid-dependent pathologies has a number of advantages over other schemes of treatment of pathologies in the gastroduodenal area.